We are live on
!
Find out more
EEG
E.E. Geduld Portfolio holdings
AUM
$178M
1-Year Est. Return
29.34%
This Fund
S&P 500
This Quarter
Est. Return
+20.65%
1 Year Est. Return
+29.34%
3 Year Est. Return
+59.91%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$100M
AUM Growth
+$24.3M
(+32%)
Cap. Flow
+$6.54M
Cap. Flow
% of AUM
6.51%
Top 10 Holdings %
Top 10 Hldgs %
56.12%
Holding
218
New
50
Increased
37
Reduced
21
Closed
27
Avg Time Held Equity + Options
4.4
quarters
Top 10 Avg Time Held Equity + Options
1.9
quarters
Top 20 Avg Time Held Equity + Options
2.2
quarters
Avg Time Held Equity only
4.7
quarters
Top 10 Avg Time Held Equity only
2.6
quarters
Top 20 Avg Time Held Equity only
2.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.77M |
| 2 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
+$661K |
| 3 |
Agios Pharmaceuticals
AGIO
|
+$653K |
| 4 |
Micron Technology
MU
|
+$610K |
| 5 |
MLNX
Mellanox Technologies, Ltd.
MLNX
|
+$487K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$1.06M |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$823K |
| 3 |
HTWR
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
|
+$578K |
| 4 |
BVA
CORDIA BANCORP INC COM
BVA
|
+$499K |
| 5 |
Opko Health
OPK
|
+$349K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 43.64% |
| 2 | Miscellaneous | 21.13% |
| 3 | Healthcare | 14.92% |
| 4 | Technology | 7.13% |
| 5 | Consumer Discretionary | 4.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
126
MannKind Corp
MNKD
$1.01B
| $47K | 0.05% |
+15,000
| New | +$66.3K |
2016 Q3
0 quarters
|
|
|
ROX
127
DELISTED
Castle Brands, Inc.
ROX
| $44K | 0.04% |
50,000
| – | – |
2013 Q2
13 quarters
|
|
128
DELISTED
Associated Banc-Corp Warrants
ASB.WS
| $43K | 0.04% |
17,000
| – | – |
2013 Q2
13 quarters
|
|
|
CGRN
129
DELISTED
Capstone Green Energy Corporation Common Stock
CGRN
| $41K | 0.04% |
+3,000
| New | +$44.5K |
2016 Q3
0 quarters
|
|
|
GCVRZ
130
DELISTED
Sanofi Contingent Value Rights
GCVRZ
| $34K | 0.03% |
125,000
| – | – |
2013 Q2
13 quarters
|
|
131
Fortress Biotech
FBIO
$70M
| $30K | 0.03% |
667
| – | – |
2013 Q2
13 quarters
|
|
132
Globalstar
GSAT
$10.8B
| $30K | 0.03% |
1,667
| – | – |
2013 Q4
11 quarters
|
|
|
CNTF
133
DELISTED
China TechFaith Wireless Communication Technology Ltd
CNTF
| $27K | 0.03% |
10,000
| – | – |
2016 Q1
2 quarters
|
|
134
Curis
CRIS
$1.55M
| $26K | 0.03% |
5
| – | – |
2013 Q2
13 quarters
|
|
|
DXTR
135
DELISTED
Dextera Surgical Inc.
DXTR
| $25K | 0.02% |
13,400
| – | – |
2016 Q2
1 quarter
|
|
136
DELISTED
Hennessy Capital Acquisition Corp. II
HCACW
| $25K | 0.02% |
63,100
+600
| +1% | +$267 |
2016 Q2
1 quarter
|
|
|
TCF.WS
137
DELISTED
TCF Financial Corporation
TCF.WS
| $24K | 0.02% |
15,100
| – | – |
2013 Q2
13 quarters
|
|
138
DELISTED
REPUBLIC AWYS HLDGS INC
RJET
| $23K | 0.02% |
25,000
-10,000
| -29% | -$9.2K |
2016 Q1
2 quarters
|
|
|
NXEOW
139
DELISTED
Nexeo Solutions, Inc. Warrant
NXEOW
| $22K | 0.02% |
34,992
-10,008
| -22% | -$6.96K |
2016 Q2
1 quarter
|
|
140
DELISTED
Bank Of America Corporation Ws B
BAC.WS.B
| $18K | 0.02% |
175,000
| – | – |
2013 Q2
13 quarters
|
|
|
EMIS
141
DELISTED
EMISPHERE TECHNOLOGIES INC
EMIS
| $14K | 0.01% |
20,000
| – | – |
2013 Q2
13 quarters
|
|
142
DELISTED
Cel-Sci Corp Series S
CVM.WS
| $12K | 0.01% |
100,000
| – | – |
2014 Q2
9 quarters
|
|
|
ELECW
143
DELISTED
Electrum Special Acquisition Corporation
ELECW
| $11K | 0.01% |
50,000
| – | – |
2015 Q4
3 quarters
|
|
144
DELISTED
DarioHealth Corp. Warrant
DRIOW
| $7K | 0.01% |
+10,000
| New | +$8.07K |
2016 Q3
0 quarters
|
|
|
IMNP
145
DELISTED
Immune Pharmaceuticals Inc.
IMNP
| $7K | 0.01% |
1,250
| – | – |
2014 Q3
8 quarters
|
|
|
OPXAW
146
DELISTED
Opexa Therapeutics, Inc.
OPXAW
| $6K | 0.01% |
+60,200
| New | +$5.51K |
2016 Q3
0 quarters
|
|
147
DELISTED
Citigroup Inc
C.WS.A
| $4K | ﹤0.01% |
75,000
| – | – |
2013 Q2
13 quarters
|
|
|
ANDAR
148
DELISTED
Andina Acquisition Corp. II Right
ANDAR
| $4K | ﹤0.01% |
12,500
| – | – |
2016 Q2
1 quarter
|
|
|
ANDAW
149
DELISTED
Andina Acquisition Corp. II Warrant
ANDAW
| $2K | ﹤0.01% |
12,500
| – | – |
2016 Q2
1 quarter
|
|
150
CALL
Acadia Pharmaceuticals
ACAD
$3.36B
| – | – |
-10,000
| Closed | -$325K | – |
|
Similar funds
BC
PFM
SRP
CF
SA
WSA
SIG
VWM
E.E. Geduld's Q3 2016 Portfolio in Review
As of Q3 2016, E.E. Geduld held 218 positions worth $100M, up 32% from $76M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
E.E. Geduld deployed $6.54M of net new capital in Q3 2016, opening 50 new positions and adding to 37 existing holdings. Its largest new stake was Agios Pharmaceuticals: 15,000 shares worth $792K.
By sector, the portfolio is most concentrated in Financials at 44% of assets, down from 49% a quarter earlier, followed by Miscellaneous and Healthcare.
On the sell side, the largest reduction was Opko Health, an estimated $349K trimmed.
- E.E. Geduld's largest Q3 2016 buy was Agios Pharmaceuticals: 15,000 shares worth $792K.
- E.E. Geduld added most to Bristol-Myers Squibb in Q3 2016, an estimated $1.77M increase.
- E.E. Geduld's biggest Q3 2016 reduction was Opko Health, cutting an estimated $349K.
- E.E. Geduld fully exited Tesla in Q3 2016, selling an estimated $1.06M.
- E.E. Geduld's ten largest holdings make up 56% of its $100M portfolio in Q3 2016.
- E.E. Geduld opened 50 new positions and closed 27 in Q3 2016.
- E.E. Geduld's portfolio value rose 32% quarter-over-quarter to $100M.
Based on E.E. Geduld's 13F filing for Q3 2016, filed 2 Nov 2016.